On July 1, Medicare will begin covering certain GLP-1 receptor agonists for patients with established cardiovascular disease and obesity or overweight, a move that alters the landscape for an entire class of metabolic drugs. The policy, driven by the 2024 CMS National Coverage Determination, explicitly includes semaglutide (Wegovy) and tirzepatide (Zepbound) when prescribed for secondary prevention of heart attack and stroke. Retatrutide, a triple-agonist still in phase 3 trials, is not named in the decision, but the precedent set by this expansion could determine how quickly and widely a future approval is adopted by payers.
The July 1 Policy: What Medicare Will Cover
Medicare Part D plans will now reimburse for semaglutide and tirzepatide when used to reduce cardiovascular risk in adults with a body mass index of 27 or higher and a history of heart disease. This follows the SELECT trial, published by Lincoff et al. in the New England Journal of Medicine in 2023, which showed a 20% reduction in major adverse cardiovascular events with semaglutide. The list price for a month of semaglutide runs around $1,349; tirzepatide sits near $1,023. Even with negotiated rebates, the cost to Medicare will be substantial, the Congressional Budget Office estimates the new coverage could add $35 billion in federal spending over a decade.
For patients, out-of-pocket costs will vary by plan. A typical Part D beneficiary might pay $200 to $300 per month after deductibles and coinsurance. But the policy excludes drugs used solely for weight loss, a distinction that creates friction for triple-agonists like retatrutide, which are being studied for both obesity and cardiometabolic endpoints. Researchers at Eli Lilly, who are developing retatrutide, reported in a 2023 phase 2 trial in The Lancet that the drug reduced body weight by up to 24% at 48 weeks, more than the 15% seen with semaglutide in earlier studies. Yet without a completed cardiovascular outcomes trial, Medicare has no data to anchor a coverage decision.
Retatrutide's Mechanism and the Evidence Gap
Retatrutide activates GLP-1, GIP, and glucagon receptors, a triple-agonist profile that sets it apart from the dual-agonist tirzepatide. In a 2022 review by Rosenstock and Frias in Diabetes Care, the glucagon component was linked to increased energy expenditure and hepatic fat reduction, effects that could translate into cardiovascular benefit. But the pivotal phase 3 trials, including TRIUMPH-1 and TRIUMPH-3, are not expected to read out until 2026. Until then, Medicare's new coverage framework offers no pathway for a drug that lacks a labeled cardiovascular indication.
This timing matters because the GLP-1 field is moving fast. A 2019 trial of tesamorelin, a growth-hormone-releasing hormone analog, showed visceral fat reduction in HIV patients but no cardiovascular outcomes data. Similarly, MOTS-c, a mitochondrial-derived peptide, has shown metabolic improvements in animal models, but human trials are sparse. The Medicare policy draws a hard line: pay for what is proven, not what is promising. For a deeper look at how retatrutide stacks up against the current standard, see the head-to-head analysis of retatrutide and semaglutide in recent GLP-1 research.
Cost Pressures and the Triple-Agonist Pipeline
Price will be a decisive factor. Semaglutide's net price after rebates is estimated at $700 to $900 per month, and tirzepatide follows a similar curve. Retatrutide, if approved, would likely enter at a premium, analysts at Evaluate Pharma project a launch price above $1,200 per month, reflecting the triple mechanism. But Medicare's new negotiating power under the Inflation Reduction Act could compress that. The first 10 drugs selected for price negotiation in 2023 saw cuts of 38% to 79% off list prices. A triple-agonist with superior efficacy might still command a higher tier, but only if it can show outcomes that justify the spend.
Other peptides in development face an even steeper climb. AOD-9604, a fragment of human growth hormone, has been studied for obesity since the early 2000s but never completed a large phase 3 trial. Its monthly cost, if commercialized, might run $150 to $300, far less than retatrutide, but without Medicare coverage, patient access would be limited to cash-pay clinics. The July 1 policy reinforces a two-tier system: drugs with robust cardiovascular data get broad coverage; those without it remain niche products.
What the Policy Means for Future Access
The CMS decision signals that payers will increasingly demand hard outcomes, not just weight loss, for broad reimbursement. For retatrutide, this means the ongoing cardiovascular outcomes trial, expected to enroll 15,000 patients, is not just a regulatory hurdle, it is the key to unlocking Medicare's formulary. If the trial shows a reduction in heart attacks or strokes comparable to semaglutide, coverage could follow within a year of FDA approval. If not, retatrutide might be relegated to the commercial insurance market, where prior authorization and step therapy are common.
This shift also affects how clinicians think about prescribing. A 2024 survey by the American College of Cardiology found that 68% of cardiologists would be more likely to prescribe a GLP-1 drug if it had a Medicare-covered cardiovascular indication. For triple-agonists, the bar is higher: they must prove they are not just better for weight loss, but better for the heart. The July 1 policy is a bet on that evidence, and the clock is ticking for retatrutide to deliver.
Where this article references real research, citations are provided so that readers may evaluate the underlying evidence directly.
Share This Article